

Special Issue

Clinical Effect and Immunologic Response after Dendritic Cell-Based Immunotherapy

Message from the Guest Editors

This special issue aims to focus on the progress of immune monitoring methodology and clinical investigation using dendritic cell (DC)-based cancer immunotherapy including precision medicine. The standardized protocol for manufacturing a dendritic cell vaccine, the selection of tumor-associated antigens (TAAs), and the process for application of dendritic and related cells will also be covered in this issue. A DC vaccine containing TAAs produced under an optimized manufacturing protocol is a potentially promising cell-based cancer immunotherapy to induce acquired immunity. Antigen-presenting ability in an *in vitro* cytotoxic T lymphocyte (CTLs) assay with TAAs is one of the main issues encountered when using DC-based vaccines in patients with cancer. Tetramer analysis and enzyme-linked immunosorbent spot (ELISpot) assays have been performed as immune monitoring for TAA-specific CTLs; however, sensitivity and specificity remain issues to be solved. A useful approach to detect TAA-specific CTLs would be expected using genomic medicine with single cell sequencing technology.

Guest Editors

Prof. Dr. Shigetaka Shimodaira

Prof. Dr. Shigeo Koido

Prof. Dr. Hitoshi Kanno

Deadline for manuscript submissions

closed (31 May 2021)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/44221

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).